Industry/Academic Research CoI Guidelines Urged By Beckman Coulter CEO
This article was originally published in The Gray Sheet
Executive Summary
Voluntary guidelines stipulating conflicts of interest between medical product manufacturers and academic facilities pursuing joint R&D should include a certification and inspection component, Beckman Coulter CEO John Wareham suggested Oct. 7
You may also be interested in...
Financial Conflict In Trials Should Be Ignored In Complex Cases – AdvaMed
Medical technology inventors should be permitted to participate as clinical trial investigators provided their interests are disclosed beforehand, AdvaMed claims in comments to an HHS proposal regulating financial conflict of interests in medical studies
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.